|
Hello fellow investors / traders,
Check out Sunshine Biopharma Inc (SBFM), it could be on the verge of a technical breakout.
If you've thought Ebola has
gone away, you are wrong. And if you missed out on some of the high
flying ebola plays recently, fear not.
We came across SBFM recently, patiently waiting
for the right time to alert this one to you. And after watching it hold
support yesterday, we think tomorrow a potential technical breakout is
on the cards.
With multi-day support at around $0.065, and
technical resistance at $0.10, SBFM is in a tight trading range. We
think with the news released this week, SBFM could break out of this range in a major way.
And as usual, getting in early while the stock is trading near support is the key to reducing risk and increasing reward.
Volume precedes price in trading, and the past couple days we've seen strong volume come in. Now we think price will follow and then the breakout through $0.10.
About SBFM...
SBFM is committed to developing novel therapies for the
treatment of various forms of aggressive cancer types. Their initial drug
candidate, Adva-27a, is a small molecule that has proven effective
against different types of multidrug resistant cancer cell lines
including breast cancer (MCF-7/MDR), small-cell lung cancer (H69AR),
uterine carcinoma (MES-SA/Dx5) and pancreatic cancer (Panc-1).
Adva-27a is SBFM's lead anticancer compound, a
Topoisomerase II inhibitor, small molecule that has recently been shown
to be effective at killing Multidrug Resistant Breast Cancer cells,
Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic
Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages
4423-4432, October 2012). Adva-27a is currently in the IND-Enabling
stage of development. The original U.S. patent covering Adva-27a was
issued on August 7, 2012 under U.S. patent number 8,236,935.
The Company
is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer
in parallel to the Phase I clinical trial of Adva-27a for multidrug
resistant Breast Cancer to be conducted at McGill University's Jewish
General Hospital in Montreal (Canada).
Major News Just Released...
A couple of days ago SBFM announced this blockbuster news that its anti-cancer compound Adva-27a could potentially be used to treat the Ebola virus.
Ebola Virus Infections Could Potentially Be Treated With Sunshine Biopharma's Lead Anticancer Compound, Adva-27a
Montreal, Quebec / ACCESSWIRE / November 3, 2014 / Sunshine Biopharma Inc. (SBFM),
a pharmaceutical company focused on the research, development and
commercialization of drugs for the treatment of various forms of cancer,
today announced that it has conducted a scientific review of the
mechanisms by which Ebola virus penetrates human cells and takes over
their machinery to multiply rapidly and go on to infecting other cells
leading to massive cell destruction and ultimately death in nearly 80%
of the cases.
The review found that the progression of Ebola virus
infection is very similar to that of Influenza A virus, the causative
agent that was responsible for the death of over 90 million people in
the 1918 flu pandemic. In severe Influenza A virus infections, a
condition associated with high mortality rate called haemophagocytic
lymphohistiocytosis (HLH) is developed by the affected patient. HLH has
previously been treated successfully with Etoposide which increased
survivability from 50% to 90% (LANCET, Volume 367, Pages 870-873, March
2006).
Etoposide is an anticancer drug that inhibits the activity
Topoisomerase II, an essential enzyme found in hyperactive, rapidly
growing cells such as cancer cells and HLH cells. Like Etoposide,
Sunshine Biopharma's lead anticancer compound, Adva-27a, is a
Topoisomerase II inhibitor however it has been shown to be more
effective and less toxic than Etoposide (ANTICANCER RESEARCH, Volume 32,
Pages 4423-4432, October 2012). The latter characteristics make
Adva-27a superior to Etoposide for possible treatment of Ebola patients
with already weakened state of health.
"We are heartened by the
possibility that our Adva-27a can potentially be used to treat Ebola in
the event there is a need," noted Dr. Steve N. Slilaty, CEO of Sunshine
Biopharma.
More Recent Headlines...
The chart on SBFM looks hot, the news coming out of the company is even hotter. Make sure you do your research on SBFM right now, and be ready to trade this potential breakout play.
www.ShiznitStocks.com
Disclaimer
Never invest in any stock featured on our
site or emails unless you can afford to lose your entire investment. For full
disclaimer click here.
ShiznitStocks.com employees are not registered as an Investment Adviser in any
jurisdiction whatsoever. The disclaimer is to be read and fully understood
before using our site, or joining our email list. None of the materials or
advertisements herein constitute offers or solicitations to purchase or sell
securities of the companies profiled herein and any decision to invest in any
such company or other financial decisions should not be made based upon the
information provide herein. Instead ShiznitStocks.com strongly urges you
conduct a complete and independent investigation of the respective companies
and consideration of all pertinent risks. ShiznitStocks.com does not offer such
advice or analysis, and ShiznitStocks.com further urges you to consult your own
independent tax, business, financial and investment advisors. Investing in
micro-cap and growth securities is highly speculative and carries and extremely
high degree of risk. It is possible that an investor's investment may be lost
or impaired due to the speculative nature of the companies profiled. Any
statements that express or involve discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, goals, assumptions or
future events or performance are not statements of historical fact may be
"forward looking statements". Forward looking statements are based on
expectations, estimates, and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through use of
words such as "projects", "foresee", "expects",
"will", "anticipates", "estimates",
"believes", "understands", or that by statements indicating
certain actions "may", "could", or "might" occur.
Understand there is no guarantee past performance will be indicative of future
results. In preparing this publication, ShiznitStocks.com has relied upon
information supplied by its customers, and press releases which it believes to
be reliable; however, such reliability cannot be guaranteed. Investors should
not rely on the information contained in this website. Rather, investors should
use the information contained in this website as a starting point for doing
additional independent research on the featured companies. The advertisements
in this website are believed to be reliable, however, ShiznitStocks.com and its
owners, affiliates, subsidiaries, officers, directors, representatives and
agents have not completed any due diligence or research on the companies advertised
herein and disclaim any liability as to the completeness or accuracy of the
information contained in any advertisement and for any omissions of materials
facts from such advertisement. ShiznitStocks.com is not responsible for any
claims made by the companies advertised herein. ShiznitStocks.com may receive
compensation and its employees and affiliates may own stock that they have
purchased in the open market either prior, during, or after the release of the
companies profile which is an inherent conflict of interest in
ShiznitStocks.com statements and opinions and such statements and opinions
cannot be considered independent. ShiznitStocks.com reserves the right to buy
and sell shares of the profiled company on the open market before, during or
after the release of the company profile. In such an event, ShiznitStocks.com
will not update its disclaimer to reflect any shares bought or sold on the open
market during the profile coverage. ShiznitStocks.com and its management may
benefit from any increase in the share price of the profiled companies and hold
the right to sell the shares bought at any given time including shortly after
the release of the companies profile. ShiznitStocks.com has
been compensated two thousand dollars via electronic transfer from a non-affiliated third party for the
profile of SBFM. ShiznitStocks.com may on occasion accept compensation in
restricted or free-trading shares for it's marketing services of the company
being profiled, and the third party that might have compensated ShiznitStocks.com
may hold free-trading shares of the company being profiled and could very well
be selling shares of the companies stock at the same time the profile is being
disseminated to potential investors; this should be viewed as a definite
conflict of interest and as such, the reader should take this into
consideration. If ShiznitStocks.com ever accepts compensation in the form
of restricted or free trading shares of the company being profiled and decides
to sell these shares into the public market at any time before, during, or
after the release of the companies profile our disclaimer will be updated
accordingly reflecting the current position of those free trading shares
received as compensation for our services. |